Cite
SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target.
MLA
Jingjing Ma, et al. “SPARC Inhibits Breast Cancer Bone Metastasis and May Be a Clinical Therapeutic Target.” Oncology Letters, vol. 14, no. 5, Nov. 2017, pp. 5876–82. EBSCOhost, https://doi.org/10.3892/ol.2017.6925.
APA
Jingjing Ma, Sheng Gao, Xiju Xie, Erhu Sun, Min Zhang, Qian Zhou, & Cheng Lu. (2017). SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target. Oncology Letters, 14(5), 5876–5882. https://doi.org/10.3892/ol.2017.6925
Chicago
Jingjing Ma, Sheng Gao, Xiju Xie, Erhu Sun, Min Zhang, Qian Zhou, and Cheng Lu. 2017. “SPARC Inhibits Breast Cancer Bone Metastasis and May Be a Clinical Therapeutic Target.” Oncology Letters 14 (5): 5876–82. doi:10.3892/ol.2017.6925.